封面
市場調查報告書
商品編碼
2173546

23價肺炎鏈球菌多醣體疫苗市場:全球市場預測,2026-2032年

23-Valent Pneumococcal Polysaccharide Vaccine Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,23 價肺炎鏈球菌多醣體疫苗市場將成長至 17.7 億美元,複合年成長率為 7.72%。

主要市場統計數據
基準年 2025 10.5億美元
預計年份:2026年 11.3億美元
預測年份 2032 17.7億美元
複合年成長率 (%) 7.72%

23價肺炎鏈球菌多醣體疫苗(PPSV23)旨在預防由23種肺炎鏈球菌血清型引起的侵襲性疾病和肺炎。其使用取決於年齡、潛在疾病、先前疫苗接種史、國家免疫政策以及公共衛生部門的建議。由於不同族群所需的預防效力和接種程序各不相同,因此,對患者進行臨床評估並嚴格遵守當地指南對於有效實施至關重要。

肺炎鏈球菌預防和疫苗接種系統的變革性變化

肺炎鏈球菌預防正朝著基於風險的疫苗接種途徑轉變,這種途徑不僅區分老年人,也免疫力缺乏者、慢性病患者和其他高風險族群。許多地區正越來越多評估23價肺炎球菌多醣疫苗(PPSV23)和肺炎球菌結合疫苗聯合接種的可行性,疫苗接種順序和時間根據國家指南確定。常規成人免疫接種計劃、藥房服務、電子提醒、改進的採購系統以及改善服務不足人群疫苗接種途徑的舉措,也都在影響著疫苗的供應。

人工智慧對肺炎鏈球菌疫苗接種的影響

人工智慧 (AI) 可以推廣提供支援。分析技術還可以幫助公共衛生團隊識別地理或人口統計差異、改善預約安排並監測安全訊號。這些應用需要檢驗的臨床規則、代表性的數據、隱私保護、人工監督,以及決策支援與處方/給藥決策之間的明確區分。

六個公共衛生領域的區域性見解

北美地區普遍受益於完善的成人免疫接種指南、廣泛的醫療基礎設施和多種疫苗接種途徑,但由於保險覆蓋範圍、地區因素和民眾信心水平等原因,疫苗接種的可及性和接種率仍然存在差異。歐洲擁有強大的公共衛生體系,但各國的免疫接種計畫、報銷機制和建議各不相同。亞太地區既有成熟的免疫接種體系,也有快速發展的醫療服務,因此實施需求也各不相同。拉丁美洲在應對經濟負擔、基層醫療可近性和疫苗供應連續性等挑戰的同時,持續加強成人和基於風險的免疫接種。中東地區的政策、醫療體系和居住人口組成有顯著差異。非洲的優先事項包括成人風險識別、加強冷鍊和基層醫療體系、資金籌措以及提高公眾意識,特別是針對合併症患者和愛滋病毒感染者。

區域洞察:東協、金磚國家、歐盟、七國集團、海灣合作理事會、北約

由於東協成員國醫療衛生系統能力和國家建議的差異,它們在區域協調、可靠採購和成人風險資訊方面面臨著特殊的挑戰。金磚國家人口眾多且構成複雜,有機會在根據區域疾病負擔調整政策的同時,加強監測、提升國內生產能力和確保公平取得。歐盟受益於協調一致的科學和監管框架,但疫苗接種計畫和資金方面的決策仍主要由各成員國自行決定。儘管七國集團的醫療衛生系統通常擁有健全的成人免疫基礎設施和數據處理能力,但涵蓋那些難以接種疫苗和醫療服務不足的人仍然是一項挑戰。海灣合作理事會國家可以利用集中採購系統和現代化的醫療衛生網路,而北約成員國則可能更加重視在緊急情況下保障基本醫療衛生服務的連續性以及保護弱勢群體。

各國視角:政策與實施考量

澳洲、加拿大、法國、德國、義大利、日本、英國、英國和美國已建立疫苗接種體系,但不同地區的接種資格標準、結合疫苗接種順序、資金籌措和接種環境各不相同。巴西、中國、印度、墨西哥、俄羅斯和韓國擁有強大的醫療衛生能力,但不同地區的疫苗接種服務、監測和成人免疫規劃也存在差異。在這些國家,實際的優先事項包括:維持準確的疫苗接種記錄、將疫苗接種建議納入基層醫療服務、加強對老年人和高危險群的宣傳,以及確保疫苗產品的穩定供應。各國在決策時應遵循相關衛生部門的最新指南,而不是想當然地認為某些做法可以跨國通用。

產業和公共衛生領導者可採取的優先事項

領導者必須使產品教育、臨床決策支援和患者資訊與當前的國家建議保持一致,尤其是在將23價肺炎球菌多醣疫苗(PPSV23)作為更廣泛的肺炎球菌疫苗接種計劃的一部分時。加強與基層醫療機構、藥局、醫院和社區組織的合作可以提高符合接種條件的成年人的識別率和覆蓋率。投資於可互通的免疫接種記錄、提醒系統、人力資源開發和透明的安全資訊傳播可以減少錯過接種機會的情況。採購計畫應包括供應彈性、公平分配、妥善儲存和疫苗接種數據監測,評估不僅應關注接種量,還應關注接種率和重點人群中可預防疾病的減少。

調查方法:基於證據的執行綜合分析

本執行摘要基於所提供的市場定義(23價肺炎球菌多醣體疫苗),整合了既定的公共衛生和臨床考量,但未包含任何市場估算、預測、市場佔有率或公司特定聲明。分析重點在於疫苗使用、政策演變、醫療服務體系、數位化工具、地區、人群以及各國具體實施情況。建議和產品供應情況可能會發生變化,相關解讀應根據國家免疫管理機構、認可的公共衛生機構、監管文件、同行評審證據以及當地流行病學檢驗的最新指南進行驗證。

結論:透過協調實施提高預防效果

依照適用的臨床指引使用時,23價肺炎鏈球菌多醣體疫苗(PPSV23)仍是預防某些成人和高風險族群肺炎鏈球菌感染的關鍵組成部分。其公共衛生價值遠不止於疫苗的可及性。準確的合格評估、適當的接種順序、可靠的配送、知情接受度以及持續的監測都至關重要。醫療保健系統、地方醫療機構、數位基礎設施和採購網路之間的協調努力將有助於消除免疫接種方面的差異,同時確保病患安全和政策的一致性。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章:23價肺炎鏈球菌多醣體疫苗市場:依產品類型分類

  • 品牌疫苗
  • 非專利疫苗

第 8 章:23 價肺炎鏈球菌多醣體疫苗市場:依製劑分類。

  • 自閉式預填充式注射器
  • 多管瓶小瓶
  • 單劑量管瓶
  • 單劑量預填充式注射器

第9章:23價肺炎鏈球菌多醣體疫苗市場:依給藥途徑分類

  • 肌肉內注射
  • 皮下注射

第10章:23價肺炎鏈球菌多醣體疫苗市場:依包裝類型分類

  • 多劑量包裝
  • 單劑量包裝
  • 單劑量包裝

第11章:23價肺炎鏈球菌多醣體疫苗市場:依風險組別分類

  • 慢性疾病患者
    • 慢性心臟疾病
    • 慢性肺部疾病
    • 糖尿病
    • 腎臟疾病
    • 肝病
  • 老年人
  • 醫療保健專業人員
  • 免疫力缺乏低下者
    • 脾臟切除患者
    • 癌症患者和接受化療的患者
    • 愛滋病患者
    • 器官移植受者
  • 吸煙者
  • 遊客

第12章:23價肺炎鏈球菌多醣體疫苗市場:依最終用戶分類

  • 門診部
  • 診所
    • 基層醫療診所
    • 專科診所
  • 居家照護環境
  • 醫院
    • 公立醫院
    • 私立醫院
  • 研究機構
  • 疫苗接種中心

第13章:23價肺炎鏈球菌多醣體疫苗市場:依銷售管道分類

  • 離線
  • 線上

第14章:23價肺炎鏈球菌多醣體疫苗市場:依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 非洲
  • 拉丁美洲
  • 中東

第15章:23價肺炎鏈球菌多醣體疫苗市場:依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第16章:23價肺炎鏈球菌多醣體疫苗市場:依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 印度
  • 英國
  • 法國
  • 加拿大
  • 澳洲
  • 義大利
  • 韓國
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第18章:公司簡介

  • Beijing Minhai Biotechnology Co Ltd.
  • Bharat Biotech International Ltd
  • Biological E Limited
  • Chengdu Institute of Biological Products Co Ltd.
  • Chongqing Zhifei Biological Products Co Ltd.
  • CSL Ltd.
  • Dr Reddys Laboratories Limited
  • Lanzhou Institute of Biological Products Co Ltd.
  • Lupin Ltd.
  • Mankind Pharma Ltd.
  • Merck Sharp & Dohme LLC
  • Novavax Inc.
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • Serum Institute of India Pvt Ltd
  • Shanghai Institute of Biological Products Co Ltd.
  • Sinopharm Group Co Ltd.
  • Sinovac Biotech Ltd.
  • SK Bioscience Co Ltd.
  • Yuxi Walvax Biotechnology Co Ltd.

第19章 主要專家

Product Code: MRR-562C14C35C96

The 23-Valent Pneumococcal Polysaccharide Vaccine Market is projected to grow by USD 1.77 billion at a CAGR of 7.72% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.05 billion
Estimated Year [2026] USD 1.13 billion
Forecast Year [2032] USD 1.77 billion
CAGR (%) 7.72%

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is designed to protect against invasive disease and pneumonia associated with 23 Streptococcus pneumoniae serotypes. Its use is shaped by age, underlying medical conditions, prior vaccination, national immunization policy, and recommendations from public-health authorities. Because protection and scheduling requirements differ across populations, effective deployment depends on clinically appropriate patient assessment and alignment with local guidance.

Transformative Shifts in Pneumococcal Prevention and Delivery

Pneumococcal prevention is shifting toward risk-based vaccination pathways that distinguish older adults from people with immunocompromising conditions, chronic diseases, or other elevated risks. Many jurisdictions increasingly evaluate PPSV23 alongside pneumococcal conjugate vaccines, with product sequence and timing determined by national recommendations. Delivery is also being influenced by routine adult immunization, pharmacy-based services, electronic reminders, strengthened procurement systems, and efforts to improve access among underserved populations.

How Artificial Intelligence Is Influencing Pneumococcal Vaccination

Artificial intelligence can support pneumococcal vaccination programs by identifying patients who may be eligible from electronic health records, reconciling prior immunization histories, and prioritizing outreach according to age and clinical risk. Analytics may also help public-health teams identify geographic or demographic gaps, improve appointment planning, and monitor safety signals. These applications require validated clinical rules, representative data, privacy safeguards, human oversight, and clear separation between decision support and prescribing or administration decisions.

Regional Insights Across Six Public-Health Environments

North America generally benefits from established adult immunization guidance, broad healthcare infrastructure, and multiple vaccination channels, while access and uptake can still vary by insurance status, geography, and trust. Europe combines strong public-health capacity with differing national schedules, reimbursement arrangements, and recommendations across countries. Asia-Pacific includes mature immunization systems alongside rapidly expanding healthcare access, creating varied implementation needs. Latin America continues to strengthen adult and risk-based vaccination while addressing affordability, primary-care reach, and supply continuity. The Middle East shows substantial variation in policy, healthcare capacity, and expatriate populations. Africa's priorities include improving adult-risk identification, cold-chain and primary-care capacity, financing, and awareness, particularly for people with comorbidities and those living with HIV.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN members face diverse health-system capabilities and national recommendations, making regional coordination, reliable procurement, and adult-risk communication especially important. BRICS countries span large and varied populations, with opportunities to strengthen surveillance, domestic production capabilities, and equitable access while adapting policies to local disease burdens. The European Union benefits from coordinated scientific and regulatory structures, but vaccination schedules and funding decisions remain primarily national. G7 systems typically have stronger adult immunization infrastructure and data capacity, with persistent challenges in reaching hesitant or medically underserved groups. GCC countries can leverage centralized procurement and modern healthcare networks, while NATO members may place additional emphasis on continuity of essential health services and protection of medically vulnerable populations during emergencies.

Country Insights: Policy and Delivery Considerations

Australia, Canada, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States have established vaccination systems, but eligibility criteria, sequencing with conjugate vaccines, funding, and delivery settings differ by jurisdiction. Brazil, China, India, Mexico, Russia, and South Korea combine substantial healthcare capabilities with regional variation in access, surveillance, and adult immunization implementation. Across these countries, practical priorities include maintaining accurate vaccination records, integrating recommendations into primary care, improving outreach to older adults and high-risk patients, and ensuring consistent product availability. National decisions should follow current guidance from the relevant health authorities rather than assuming that practices are transferable across borders.

Actionable Priorities for Industry and Public-Health Leaders

Leaders should align product education, clinical decision support, and patient communications with current national recommendations, especially where PPSV23 is used within a broader pneumococcal vaccination sequence. Strengthening partnerships with primary-care practices, pharmacies, hospitals, and community organizations can improve identification and reach of eligible adults. Investments in interoperable immunization records, reminder systems, workforce training, and transparent safety communication can reduce missed opportunities. Procurement planning should include supply resilience, equitable allocation, appropriate storage, and monitoring of administration data, while evaluation should focus on coverage among priority groups and reduction of preventable disease rather than volume alone.

Research Methodology: Evidence-Based Executive Synthesis

This executive summary uses the supplied market definition-23-valent pneumococcal polysaccharide vaccine-and synthesizes established public-health and clinical considerations without introducing market estimates, forecasts, shares, or company-specific claims. The analysis is structured around vaccine use, policy evolution, healthcare delivery, digital tools, geography, population groupings, and country implementation. Interpretations should be validated against current guidance from national immunization authorities, recognized public-health agencies, regulatory documents, peer-reviewed evidence, and local epidemiological surveillance because recommendations and product availability can change.

Conclusion: Improving Protection Through Coordinated Implementation

PPSV23 remains an important component of pneumococcal disease prevention for selected adults and high-risk populations when used according to applicable clinical guidance. Its public-health value depends on more than vaccine availability: accurate eligibility assessment, appropriate sequencing, reliable delivery, informed acceptance, and sustained monitoring are all essential. Coordinated action across health systems, community providers, digital infrastructure, and procurement networks can help close immunization gaps while preserving patient safety and policy consistency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Product Type

  • 7.1. Introduction
  • 7.2. Branded Vaccine
  • 7.3. Generic Vaccine

8. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Formulation

  • 8.1. Introduction
  • 8.2. Auto-disable Prefilled Syringe
  • 8.3. Multi Dose Vial
  • 8.4. Single Dose Glass Vial
  • 8.5. Single Dose Prefilled Syringe

9. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intramuscular Injection
  • 9.3. Subcutaneous Injection

10. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Packaging

  • 10.1. Introduction
  • 10.2. Multi-Dose Packaging
  • 10.3. Single-Dose Packaging
  • 10.4. Unit Dose Packs

11. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Risk Group

  • 11.1. Introduction
  • 11.2. Chronic Disease Patients
    • 11.2.1. Chronic Heart Disease
    • 11.2.2. Chronic Lung Disease
    • 11.2.3. Diabetes Mellitus
    • 11.2.4. Kidney Disease
    • 11.2.5. Liver Disease
  • 11.3. Elderly Population
  • 11.4. Healthcare Workers
  • 11.5. Immunocompromised Individuals
    • 11.5.1. Asplenic Individuals
    • 11.5.2. Cancer & Chemotherapy Patients
    • 11.5.3. HIV Patients
    • 11.5.4. Organ Transplant Recipients
  • 11.6. Smokers
  • 11.7. Travelers

12. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by End User

  • 12.1. Introduction
  • 12.2. Ambulatory Care Centers
  • 12.3. Clinics
    • 12.3.1. Primary Care Clinics
    • 12.3.2. Specialty Clinics
  • 12.4. Homecare Settings
  • 12.5. Hospitals
    • 12.5.1. Government Hospitals
    • 12.5.2. Private Hospitals
  • 12.6. Research Institutes
  • 12.7. Vaccination Centers

13. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Sales Channel

  • 13.1. Introduction
  • 13.2. Offline
  • 13.3. Online

14. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Region

  • 14.1. Introduction
  • 14.2. Asia-Pacific
  • 14.3. Europe
  • 14.4. North America
  • 14.5. Africa
  • 14.6. Latin America
  • 14.7. Middle East

15. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Group

  • 15.1. Introduction
  • 15.2. NATO
  • 15.3. G7
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. ASEAN
  • 15.7. GCC

16. 23-Valent Pneumococcal Polysaccharide Vaccine Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. China
  • 16.4. Germany
  • 16.5. Japan
  • 16.6. India
  • 16.7. United Kingdom
  • 16.8. France
  • 16.9. Canada
  • 16.10. Australia
  • 16.11. Italy
  • 16.12. South Korea
  • 16.13. Russia
  • 16.14. Brazil
  • 16.15. Mexico
  • 16.16. Spain

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Beijing Minhai Biotechnology Co Ltd.
  • 18.2. Bharat Biotech International Ltd
  • 18.3. Biological E Limited
  • 18.4. Chengdu Institute of Biological Products Co Ltd.
  • 18.5. Chongqing Zhifei Biological Products Co Ltd.
  • 18.6. CSL Ltd.
  • 18.7. Dr Reddys Laboratories Limited
  • 18.8. Lanzhou Institute of Biological Products Co Ltd.
  • 18.9. Lupin Ltd.
  • 18.10. Mankind Pharma Ltd.
  • 18.11. Merck Sharp & Dohme LLC
  • 18.12. Novavax Inc.
  • 18.13. Panacea Biotec Ltd
  • 18.14. Sanofi Pasteur SA
  • 18.15. Serum Institute of India Pvt Ltd
  • 18.16. Shanghai Institute of Biological Products Co Ltd.
  • 18.17. Sinopharm Group Co Ltd.
  • 18.18. Sinovac Biotech Ltd.
  • 18.19. SK Bioscience Co Ltd.
  • 18.20. Yuxi Walvax Biotechnology Co Ltd.

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, Years Considered for the Study
  • FIGURE 2. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, Research Design
  • FIGURE 3. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, Research Framework
  • FIGURE 4. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, Data Triangulation
  • FIGURE 5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2025 vs 2032 (%)
  • FIGURE 9. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 11. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2025 vs 2032 (%)
  • FIGURE 13. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2025 vs 2032 (%)
  • FIGURE 15. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 17. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2025 vs 2032 (%)
  • FIGURE 19. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Segmentation & Coverage
  • TABLE 2. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Branded Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Branded Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Branded Vaccine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Generic Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Generic Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Generic Vaccine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 11. Global Auto-disable Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 12. Global Auto-disable Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 13. Global Auto-disable Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 14. Global Multi Dose Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Multi Dose Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Multi Dose Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Single Dose Glass Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Single Dose Glass Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Single Dose Glass Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Single Dose Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Single Dose Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Single Dose Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 24. Global Intramuscular Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Intramuscular Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Intramuscular Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 31. Global Multi-Dose Packaging Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Multi-Dose Packaging Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Multi-Dose Packaging Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Single-Dose Packaging Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Single-Dose Packaging Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Single-Dose Packaging Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Unit Dose Packs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Unit Dose Packs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Unit Dose Packs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 41. Global Chronic Disease Patients Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Chronic Disease Patients Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Chronic Disease Patients Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Chronic Heart Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Chronic Heart Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Chronic Heart Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Chronic Lung Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Chronic Lung Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Chronic Lung Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Diabetes Mellitus Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Diabetes Mellitus Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Diabetes Mellitus Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Kidney Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Kidney Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Kidney Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Liver Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Liver Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Liver Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Elderly Population Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global Elderly Population Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global Elderly Population Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Healthcare Workers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global Healthcare Workers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global Healthcare Workers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global Immunocompromised Individuals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Immunocompromised Individuals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Immunocompromised Individuals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global Asplenic Individuals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global Asplenic Individuals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global Asplenic Individuals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Cancer & Chemotherapy Patients Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Cancer & Chemotherapy Patients Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Cancer & Chemotherapy Patients Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global HIV Patients Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global HIV Patients Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global HIV Patients Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global Organ Transplant Recipients Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Organ Transplant Recipients Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Organ Transplant Recipients Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global Smokers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Smokers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Smokers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global Travelers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global Travelers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global Travelers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 87. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 90. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 91. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 93. Global Primary Care Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Global Primary Care Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 95. Global Primary Care Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 96. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 97. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 98. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 99. Global Homecare Settings Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 100. Global Homecare Settings Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 101. Global Homecare Settings Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 102. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 103. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 104. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 105. Global Government Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 106. Global Government Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 107. Global Government Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 108. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 109. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 110. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 111. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 112. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 113. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 114. Global Vaccination Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. Global Vaccination Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. Global Vaccination Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 117. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 118. Global Offline Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 119. Global Offline Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 120. Global Offline Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 121. Global Online Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 122. Global Online Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 123. Global Online Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 124. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 125. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 126. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 127. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 128. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 129. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 130. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 131. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 132. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 133. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 134. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 135. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 136. Asia-Pacific 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 137. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 138. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 139. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 140. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 141. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 142. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 143. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 144. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 145. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 146. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 147. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 148. Europe 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 149. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 150. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 151. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 152. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 153. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 154. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 155. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 156. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 157. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 158. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 159. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 160. North America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 161. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 162. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 163. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 164. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 165. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 166. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 167. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 168. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 169. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 170. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 171. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 172. Africa 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 173. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 174. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 175. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 176. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 177. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 178. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 179. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 180. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 181. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 182. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 183. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 184. Latin America 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 185. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 186. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 187. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 188. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 189. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 190. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 191. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 192. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 193. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 194. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 195. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 196. Middle East 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 197. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 198. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 199. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 200. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 201. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 202. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 203. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 204. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 205. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 206. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 207. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 208. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 209. NATO 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 210. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 211. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 212. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 213. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 214. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 215. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 216. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 217. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 218. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 219. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 220. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 221. G7 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 222. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 223. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 224. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 225. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 226. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 227. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 228. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 229. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 230. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 231. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 232. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 233. European Union 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 234. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 235. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 236. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 237. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 238. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 239. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 240. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 241. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 242. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 243. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 244. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 245. BRICS 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 246. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 247. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 248. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 249. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 250. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 251. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 252. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 253. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 254. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 255. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 256. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 257. ASEAN 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 258. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 259. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 260. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 261. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 262. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 263. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 264. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 265. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 266. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 267. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 268. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 269. GCC 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 270. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 271. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 272. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 273. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 274. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 275. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 276. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 277. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 278. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 279. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 280. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 281. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 282. United States 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 283. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 284. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 285. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 286. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 287. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 288. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 289. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 290. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 291. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 292. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 293. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 294. China 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)
  • TABLE 295. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 296. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 297. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 298. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 299. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Packaging, 2017-2032 (USD Million)
  • TABLE 300. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Risk Group, 2017-2032 (USD Million)
  • TABLE 301. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Chronic Disease Patients, 2017-2032 (USD Million)
  • TABLE 302. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Immunocompromised Individuals, 2017-2032 (USD Million)
  • TABLE 303. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 304. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Clinics, 2017-2032 (USD Million)
  • TABLE 305. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Hospitals, 2017-2032 (USD Million)
  • TABLE 306. Germany 23-Valent Pneumococcal Polysaccharide Vaccine Market Size, by Sales Channel, 2017-2032 (USD Million)

TABLE 307.